Naslov
Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study

Autori
Mohty, Mohamad ; Terpos, Evangelos ; Mateos, Maria-Victoria ; Cavo, Michele ; Lejniece, Sandra ; Beksac, Meral ; Bekadja, Mohamed Amine ; Legiec, Wojciech ; Dimopoulos, Meletios ; Stankovic, Svetlana ; Durán, Maria Soledad ; De Stefano, Valerio ; Corso, Alessandro ; Kochkareva, Yulia ; Laane, Edward ; Berthou, Christian ; Salwender, Hans ; Masliak, Zvenyslava ; Pečeliūnas, Valdas ; Willenbacher, Wolfgang ; Silva, João ; Louw, Vernon ; Nemet, Damir ; Borbényi, Zita ; Abadi, Uri ; Pedersen, Robert Schou ; Černelč, Peter ; Potamianou, Anna ; Couturier, Catherine ; Feys, Caroline ; Thoret-Bauchet, Florence ; Boccadoro, Mario et al.

Kolaboracija
EMMOS Investigators

Izvornik
Clinical Lymphoma Myeloma & Leukemia (2152-2650) 18 (2018), 10; E401-e419

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
bortezomib ; global ; observational study ; routine practice ; stem cell transplantation

Sažetak
Abstract BACKGROUND:The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. PATIENTS AND METHODS: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias ; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. RESULTS: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non- SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. CONCLUSION: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA